Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

A new study suggests Paxlovid may not reduce the risk of covid-19 hospitalizations and all-cause deaths in vaccinated adults ...

Researchers have found in a new study that among COVID-19 patients with asthma, those who received Paxlovid had a ...

The antiviral combination of nirmatrelvir and ritonavir (brand name Paxlovid) is an effective treatment for people with COVID-19 who have mild symptoms and face a high risk of hospitalization.

The suit – filed in a Massachusetts district court – claims that Paxlovid (nirmatrelvir and ritonavir) infringes its 11,358,953 patent which covers "compounds and pharmaceutically acceptable ...

“At best, nirmatrelvir-ritonavir could reduce COVID-19–related hospitalizations by 1.3 percentage points, which is four times smaller than the absolute risk reduction of 5.5 percentage points ...

Medicare beneficiaries can get Paxlovid for free through the U.S. Government Patient Assistance Program (USG PAP) until December 31, 2025. Read more.

Paxlovid is a prescription-only oral antiviral medication containing nirmatrelvir and ritonavir. It treats mild to moderate COVID-19 symptoms and is particularly effective if you are unvaccinated.